South and Central America API market closing gap on northern neighbors
The market for active pharmaceutical ingredients (API) t in the Americas was worth a staggering $46 billion in 2011, with North America accounting for over 88% of this total. However, due to rapidly expanding economies and improvements in health care, South and Central America (SCA) are set to take a more substantial chunk in the future, according to the latest research from pharmaceutical industry analyst GBI Research.
According to the report, the SCA region has one of the fastest expanding API markets in the world, with a growing demand for generic and biologic medications. Mexico is currently the largest market in the region, but thanks to an aging population and a strengthening health care system, Brazil is expected to overtake by 2017.
Many SCA nations gaining government support
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze